Table 4Disease progression-related outcomes in trials comparing beta interferons

Study
N, duration
Intervention, doseDisease progressionaMean change in EDSSMean EDSS at endpoint
Durelli 2002
INCOMIN trial N=188, 2 years
Interferon β-1a IM (Avonex®) 30 mcg vs. Interferon β-1b SC (Betaseron®) 250 mcg30% vs. 13% P=0.00360.54 vs. 0.13 P<0.00012.5 vs. 2.1 P=0.0002
Koch-Henriksen 2006
Danish Multiple Sclerosis Study Group N=301, 2 years
Interferon β-1a SC (Rebif®) 22 mcg weekly vs. Interferon β-1b SC (Betaseron®) 250 mcg36% vs. 33% P=0.3736NRNR
Etemadifar 2006
N=90, 2 years
Interferon β-1a IM (Avonex®) 30 mcg vs. Interferon β-1a SC (Rebif®) 44 mcg vs. Interferon β-1b SC (Betaseron®) 250 mcgNR−0.1 vs. −0.3 vs. − 0.7 Interferon β-1b SC (Betaseron ®) vs. Interferon β-1a SC (Rebif®) P=0.0011.8 vs. 1.8 vs. 1.2 Interferon β-1b SC (Betaseron®) vs. Interferon β-1a SC (Rebif®) P=0.0023
Etemadifar 2007
N=47, 1 year
Interferon β-1a IM (Avonex®) 30 mcg vs. Interferon β-1a SC (Rebif®) 44 mcg vs. Interferon β-1b SC (Betaseron®) 250 mcgNR−0.2 vs −0.4 vs −0.1 P<0.051.4 (0.7 SD) vs 1.2 (0.7 SD) vs 1.4 (1.0 SD)
Panitch 2002
EVIDENCE trial N=677, 16 months
Interferon β-1a IM (Avonex®) 30 mcg vs. Interferon β-1a SC (Rebif®) 44 mcg54% vs. 57%NRNR
Pooled weighted mean difference:Interferon β-1b SC (Betaseron®) 250 mcg vs. Interferon β-1a IM (Avonex®) 30 mcg--−0.330 (95% CI, −0.686 to 0.025) I2=59.9%--
Pooled weighted mean difference EDSS:Interferon β-1a IM (Avonex®) 30 mcg vs. Interferon β-1a SC (Rebif®) 44 mcg--0.200 (95% CI, −0.076 to 0.476) I2=0%

Abbreviations: EDSS, Expanded Disability Status Scale; IM, intramuscular; NR, not reported; SD, SC, subcutaneous.

a

Weighted mean difference, random effects model.

From: Results

Cover of Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis
Drug Class Review: Disease-modifying Drugs for Multiple Sclerosis: Final Update 1 Report [Internet].
Smith B, Carson S, Fu R, et al.
Portland (OR): Oregon Health & Science University; 2010 Aug.
Copyright © 2010 by Oregon Health & Science University, Portland, Oregon 97239. All rights reserved.

NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.